Why are we doing this research?
PhaRmacogenetics Of the Glycemic RESponse to SGLT2 inhibitors, or PROGRESS, is studying dapagliflozin (Farxiga) to elucidate the role of a patient’s genetic makeup in choosing what drug to prescribe them. PROGRESS is one of the first pharmacogenetic investigations of SGLT2 inhibitors involving the acute response.
What are the aims of this study?
- Using integrated muti-omic analyses including genetics, metabolomics, and proteomics to predict the effects of SGLT2 inhibitors.
- Tailor approach to T2D treatment by considering a patient’s genetic profile in drug choices.
- Identify patients across the spectrum of T2D genetic risk and carriers of variants within SLC5A2, the gene encoding the molecular target of SGLT2 inhibitors.
- Assess whether the change in blood sugar levels due to SGLT2 inhibitors differ by T2D genetic risk or genetic variation within SLC5A2.
- Assess whether SGLT2 inhibitors effects on glycemic control and T2D-related complications are modified by genetic risk or genetic variation within SLC5A2.
What do study visits consist of?
- If you do not have recent bloodwork results, come in for a screening visit where a brief blood draw will be performed
- Two, five-hour visits a week apart
- If you have diabetes, stop your home diabetes medication for 5 days before your 1st five-hour visit
- At each visit
- Height and weight measurements
- Glucose checks
- Blood draws
- Urine collections
- Take the study drug daily for 5 days at home and once during the second visit
Who is eligible to participate?
- Age
- Not taking a GLP-1
- You do not have to have xx/xx to participate
Interested in joining?
Contact our research coordinator Rachel Huynh at (617) 726 – 6537 or send us an email at mghprogress@mgb.org